Bluebird Bio Inc BLUE

Bluebird Bio Inc is an American biotechnology company based in Cambridge, Massachusetts, serving a worldwide customer base. The firm is primarily engaged in the development and commercialisation of gene therapies targeting patients with severe genetic disorders and various types of cancer. The company was founded in 1992 as Genetix Pharmaceuticals and was renamed Bluebird Bio in 2010. The firm has a strong focus on research into specific genetic diseases, including sickle cell disease, cerebral adrenoleukodystropy (CALD), and transfusion dependent beta-thalassemia.

The company’s products include ZYNTEGLO (betibeglogene autotemcel) for the treatment of adult and adolescent patients with transfusion dependent beta-thalassemia, and SKYSONA (elivaldogene autotemcel) for the treatment of patients with CALD. The company has a number of products in its pipeline at various stages, from the pre-clinical stage to phase 3, all with a focus on the treatment of genetic diseases.

The firm works in collaboration with various partner organisations. A research collaboration with FortySeven focuses on the development of a novel antibody-based conditioning regimen, and manufacturing agreements are in place with both Minaris and Lonza. Since 2013, the company has been a public company listed on the NASDAQ, where it trades under the ticker BLUE.

Add BLUE stock to your eToro watchlist today to stay up to date on value changes.